Furthermore, inhibitors against CHK1 and BRD4 are currently trialed in combination with immunotherapies in patients with advanced solid tumors, including HCC (NCT04840589, NCT03059147, NCT03495323). The gene discussed is BRD4; the disease is hepatocellular carcinoma.